和元生物(688238.SH)：拟出资不超1亿元发起设立产业并购基金

Core Viewpoint - The cell and gene therapy sector is identified as a groundbreaking frontier with revolutionary treatment potential, becoming a core growth point in the global healthcare industry during a critical window for technological breakthroughs and industrial transformation [1] Group 1: Company Initiatives - The company plans to establish an industrial merger and acquisition fund in collaboration with Shanghai Hongsheng Junhao Equity Investment Fund Management Co., Ltd. and other partners to support its long-term strategic layout in the gene and cell therapy industry [1] - The total fundraising scale of the fund is tentatively set at RMB 500 million, with the company intending to contribute no more than RMB 100 million, representing approximately 20% of the fund's total fundraising [1] - The company does not have any obligations to guarantee returns or provide exit guarantees to other investors [1] Group 2: Fund Status - The fund is currently in the preparatory stage, with the partnership agreement yet to be finalized and the necessary business registration and filing with the Asset Management Association of China still pending [1]